Eligibility criteria include patients aged 50–70 years who are diagnosed with unicentric ER+/PR+/HER2− pT1N0 breast cancer that are also genomically characterized as low-risk by an Oncotype Dx Recurrence Score of ≤ 18. Here, ESR1 is linked to breast carcinoma.